Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Platinol (cisplatin for injection, USP)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – August 2011

 

Summary View

 

WARNINGS

  • Injection site reactions may occur during the administration of PLATINOL (seeADVERSE REACTIONS). Given the possibility of extravasation, it is recommended to closely monitor the infusion site for possible infiltration during drug administration. A specific treatment for extravasation reactions is unknown at this time.

 

ADVERSE REACTIONS

Neurotoxicity
  • leukoencephalopathy, and reversible posterior leukoencephalopathy syndrome (RPLS) have also been reported.
-
-